VOEGTLE; Markus

Patent Applications and Registrations

Patent applications and USPTO patent grants for VOEGTLE; Markus.The latest application filed is for "biaryl derivatives as yap/taz-tead protein-protein interaction inhibitors".

Company Profile

2.11.18

VOEGTLE; Markus - Lorrach CH
VOEGTLE; Markus - Basel CH
Voegtle; Markus - Loerrach N/A DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Biaryl Derivatives As Yap/taz-tead Protein-protein Interaction Inhibitors App 20210299100 - BORDAS; Vincent ; et al.	2021-09-30
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 10,683,287 - Badiger , et al.	2020-06-16
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20200048236 - Badiger; Sangamesh ; et al.	2020-02-13
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 10,301,296 - Badiger , et al.	2019-05-28
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20190062319 - Badiger; Sangamesh ; et al.	2019-02-28
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 10,035,794 - Badiger , et al. July 31, 2	2018-07-31
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20170320864 - BADIGER; Sangamesh ; et al.	2017-11-09
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 9,550,758 - Badiger , et al. January 24, 2	2017-01-24
Oxazine derivatives and their use in the treatment of disease Grant 9,284,284 - Hurth , et al. March 15, 2	2016-03-15
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20150203481 - BADIGER; Sangamesh ; et al.	2015-07-23
Oxazine Derivatives And Their Use In The Treatment Of Neurological Disorders App 20150018338 - BADIGER; Sangamesh ; et al.	2015-01-15
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 8,865,712 - Badiger , et al. October 21, 2	2014-10-21
Novel Oxazine Derivatives and their use in the Treatment of Disease App 20140256715 - Hurth; Konstanze ; et al.	2014-09-11
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20140107118 - BADIGER; Sangamesh ; et al.	2014-04-17
Heterocyclic derivatives and their use in the treatment of neurological disorders Grant 8,637,508 - Badiger , et al. January 28, 2	2014-01-28
Oxazine Derivatives and their Use in the Treatment of Neurological Disorders App 20130281449 - Hurth; Konstanze ; et al.	2013-10-24
Oxazine Derivatives And Their Use In The Treatment Of Neurological Disorders App 20120302558 - Badiger; Sangamesh ; et al.	2012-11-29
Novel Heterocyclic Derivatives and Their Use in the Treatment of Neurological Disorders App 20120184539 - BADIGER; Sangamesh ; et al.	2012-07-19
Oxazine Derivatives and their Use in the Treatment of Neurological Disorders App 20120172359 - BADIGER; Sangamesh ; et al.	2012-07-05
Oxazine Derivatives And Their Use In The Treatment Of Neurological Disorders App 20110021520 - BADIGER; Sangamesh ; et al.	2011-01-27

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.